CLDX Celldex Therapeutics, Inc.: institutional ownership and insider trading
267 funds reported holding $3.30B of Celldex Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $480M, with 46 new positions and 20 funds selling out; over the last 12 months insiders bought $0 and sold $1.30M on the open market.
Famous investors holding CLDX
- Izzy Englander (Millennium Management): $43.6M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $24.6M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $2.15M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $663K, 0.0% of the portfolio
Largest institutional holders of CLDX
- WELLINGTON MANAGEMENT GROUP LLP — $355M
- BlackRock, Inc. (BLK) — $261M
- Kynam Capital Management, LP — $198M
- PRICE T ROWE ASSOCIATES INC /MD/ — $174M
- STATE STREET CORP (STT, STT-PG) — $145M
- FMR LLC — $139M
- VANGUARD CAPITAL MANAGEMENT LLC — $129M
- VANGUARD GROUP INC — $109M
- Deep Track Capital, LP — $109M
- Logos Global Management LP — $78.1M
Recent CLDX insider trades
- Dec 4, 2025: Jimenez Freddy A. sold 4,166 shares ($121K)
- Nov 13, 2025: Wright Richard M. sold 49,298 shares ($1.18M)
- Aug 13, 2025: Jimenez Freddy A. sold 771 shares ($19.1K)
- Nov 11, 2024: Marucci Anthony S bought 11,500 shares ($308K)
5%+ owners
- FMR LLC: 10.7% (Schedule 13G/A, filed Oct 7, 2026)
- Kynam Capital Management, LP: 6.8% (Schedule 13G/A, filed Aug 14, 2026)
- T. Rowe Price Associates, Inc.: 6.0% (Schedule 13G, filed Aug 14, 2026)
- Vanguard Capital Management: 5.2% (Schedule 13G, filed Apr 29, 2026)